This 16-hour, on-demand course is the essential primer for physicians preparing for the addiction medicine examination and also serves to increase other healthcare professionals' knowledge of addiction.

This 8-hour, online course will provide an overview of the basics of addiction medicine needed to screen, diagnose, treat and/or refer patients with addiction

This 45-minute, on-demand session from the ASAM 2023 Review Course focuses on the interactions between disorders, differential diagnoses, and management as well as a framework to assess patients for psychiatric co-morbidities.

This 72.5 hour on-demand conference includes over 70 sessions highlighting best practices and the latest science, research, and innovations in addiction medicine from leading experts in the field.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses multiple strategies to expand the pharmacopeia of alcohol use disorder (AUD) therapies, including repurposing of medications that are already FDA-approved, and conducting lab-based, experimental early-phase clinical trials to provide proof-of-concept evidence for the new compounds.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses the epidemiology of diversion, as well as the ethical and societal impacts of diversion and policies aimed at limiting diversion.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses the use of ketamine to treat and/or prevent buprenorphine-precipitated opioid withdrawal in the emergency department and outpatient settings.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses how care delivery models for buprenorphine telehealth can be implemented into existing health system infrastructure.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses the pharmacology and clinical evidence for the use of slow-release oral morphine for treatment of opioid use disorder.

This 75-minute on-demand session from the ASAM 54th Annual Conference addresses how low-threshold access to high-dose extended-release buprenorphine (XR-BUP) may increase treatment duration and reduce overdose risk in rural and indigenous populations who disproportionately lack access to care.